LUNG

Stats

Summary

pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease. the company’s first commercial products address emphysema, a form of copd (chronic obstructive pulmonary disease) and the largest unmet medical need in pulmonology. with emphysema, breathing becomes increasingly more difficult as the disease progresses. today in the u.s., advanced emphysema patients have no available alternatives but lung volume reduction surgery, which is associated with high morbidity and mortality, and lung transplantation, which is limited by the availability of donor organs. pulmonx has developed the zephyr endobronchial valve (ebv) therapy, a non-surgical, investigational approach to treating emphysema. the minimally invasive zephyr valve is a tiny, one-way valve designed to reduce the volume of the diseased regions of the lung by blocking airflow, in order to improve breathing and increase activity levels. no surgery is involved in the simp

Market Cap: 341 Million

Primary Exchange: NASDAQ

Website:

Shares Outstanding: 38.5 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.2218154947761537

Sector: Manufacturing

Industry: Surgical and Medical Instrument Manufacturing

Ethical Flags

Longest drawdown: 1028 trading days

From: 2020-12-31 To: 2024-03-07

Lowest Point: